Form 4: Rocket Pharmaceuticals CEO Sells Shares for Tax Withholding

Sentiment:

Insider Transaction Filing


Rocket Pharmaceuticals CEO Gaurav Shah sold 2,409 shares of common stock for $3.014 each to cover tax obligations from vested Restricted Stock Units.

Summary

  • Gaurav Shah, CEO of Rocket Pharmaceuticals, reported a transaction on May 19, 2026.
  • He sold 2,409 shares of common stock at a price of $3.014 per share.
  • The sale was conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs).
  • Following this transaction, Shah beneficially owns 1,040,918 shares directly.
  • Additional holdings include 207,897 shares held by his spouse and 198,341 shares held by the Gaurav D. Shah Irrevocable Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale of shares by the CEO was for tax purposes related to RSU vesting, a standard procedure, rather than an indication of negative sentiment towards the company's performance.

Negatives

  • The CEO sold company stock, which can sometimes be perceived negatively by the market, although in this case it was for tax withholding purposes.

Future Outlook

No specific future outlook or guidance was provided in this filing.

Industry Context

StockSavvy.ai notes that insider stock sales for tax withholding are common events, particularly following the vesting of equity awards. The key is to distinguish these routine transactions from sales driven by a lack of confidence in the company's future prospects.

Stakeholder Impact

  • Shareholders: The sale is for tax purposes and does not necessarily reflect a change in the CEO's confidence in the company's long-term value. The impact on share price is likely minimal.
  • Employees: The transaction highlights the equity compensation structure for management, with RSUs vesting and requiring tax payments.
  • Management: The CEO is fulfilling tax obligations related to his compensation package.

Key Dates

DateDescription
05/19/2026Transaction Date (Sale of common stock)
05/21/2026Date of Report Signature

Keywords

Rocket Pharmaceuticals, RCKT, Form 4, Insider Transaction, Stock Sale, CEO, Gaurav Shah, Restricted Stock Units, Tax Withholding

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.